BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 15242608)

  • 1. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.
    Somoza JR; Skene RJ; Katz BA; Mol C; Ho JD; Jennings AJ; Luong C; Arvai A; Buggy JJ; Chi E; Tang J; Sang BC; Verner E; Wynands R; Leahy EM; Dougan DR; Snell G; Navre M; Knuth MW; Swanson RV; McRee DE; Tari LW
    Structure; 2004 Jul; 12(7):1325-34. PubMed ID: 15242608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.
    Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A
    J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
    Ortore G; Di Colo F; Martinelli A
    J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning and characterization of a novel human histone deacetylase, HDAC8.
    Buggy JJ; Sideris ML; Mak P; Lorimer DD; McIntosh B; Clark JM
    Biochem J; 2000 Aug; 350 Pt 1(Pt 1):199-205. PubMed ID: 10926844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylases--an important class of cellular regulators with a variety of functions.
    Hildmann C; Riester D; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the substrate specificity of histone deacetylases.
    Riester D; Hildmann C; Grünewald S; Beckers T; Schwienhorst A
    Biochem Biophys Res Commun; 2007 Jun; 357(2):439-45. PubMed ID: 17428445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
    Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
    Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class II histone deacetylases: structure, function, and regulation.
    Bertos NR; Wang AH; Yang XJ
    Biochem Cell Biol; 2001; 79(3):243-52. PubMed ID: 11467738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
    Hodawadekar SC; Marmorstein R
    Oncogene; 2007 Aug; 26(37):5528-40. PubMed ID: 17694092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases.
    Schultz BE; Misialek S; Wu J; Tang J; Conn MT; Tahilramani R; Wong L
    Biochemistry; 2004 Aug; 43(34):11083-91. PubMed ID: 15323567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and functional studies of the yeast class II Hda1 histone deacetylase complex.
    Lee JH; Maskos K; Huber R
    J Mol Biol; 2009 Aug; 391(4):744-57. PubMed ID: 19573535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex.
    Vannini A; Volpari C; Gallinari P; Jones P; Mattu M; Carfí A; De Francesco R; Steinkühler C; Di Marco S
    EMBO Rep; 2007 Sep; 8(9):879-84. PubMed ID: 17721440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class IIa histone deacetylases: regulating the regulators.
    Martin M; Kettmann R; Dequiedt F
    Oncogene; 2007 Aug; 26(37):5450-67. PubMed ID: 17694086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
    Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
    J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
    Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
    Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.